

DIRECT-ACTING ANTIVIRALS FOR HEPATITIS C VIRUS IN HIV CO-INFECTED PATIENTS

Contreras Rey MB, Estaire Gutiérrez J, Sánchez del Moral R, Romero Alonso MM, Bolívar Raya MA, ²Bocanegra Martín C

Infanta Elena Hospital. ²Juan Ramón Jiménez Hospital. Pharmacy. Huelva, Spain

5PSQ-046

J05 Antivirals for systemic use



BACKGROUND

The development of new direct acting antivirals (DAAs) for hepatitis C virus (HCV) represents an evolution in the treatment.

As HIV-HCV coinfection is common, evaluation of DAAs effectiveness and drug interactions with antiretroviral therapy (ART) is useful in this population.

OBJECTIVES



To assess the effectiveness of DAAs and drug interactions with ART in HIV/HCV-coinfected patients.

METHODS

- Retrospective observational study, including HIV/HCV-coinfected patients who started DAAs (August 2015 - August 2017).
- Data were obtained from outpatient software, electronic health records or interview with patients.
- Effectiveness was assessed by achievement of virological response (week 4 of treatment, end of treatment and post-treatment week 12).
- Interactions between DAAs and ART were evaluated by using University of Liverpool Drug Interaction database.

RESULTS

- 66 HIV/HCV-coinfected patients (21.2% women), mean age 50.1 years (40-57; SD 3.9).
- HCV genotype distribution: 1a (40.9%), 4 (22.7%), 3 (18.2%), 1b (16.7%) and 2 (1.5%).
- 37.9% had cirrhosis and 15.2% were pretreated HCV patients.
- Median baseline HCV viral load was 1 942 570 IU/mL.



39 potential interactions and 5 contraindications between DAAs and ART were identified, mostly only required monitoring.

Prescription of DAAs supposed: modifications in ART (12 cases) and a dose adjustment for the DAA (1 case)

Analysis date: 58 patients had finished treatment, 3 were still receiving DAAs and 5 had discontinued it.

- 63.6% had a rapid virological response (**week 4 of treatment**).
- In patients who completed DAA regimens: 92.1% had undetectable viral load at the **end of treatment**.
- Of 54 patients who reached **post-treatment week 12**: 50 had sustained virological response, 2 presented detectable viral load (resistance mutations were found) and 2 had missed data.

CONCLUSIONS

DAAs have shown a high effectiveness in HIV/HCV co-infected patients. In this population, it's essential an appropriate revision and management of drug interactions with ART.